These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 38229377)
21. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Tanaka Y; Tummala R Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461 [TBL] [Abstract][Full Text] [Related]
22. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096 [TBL] [Abstract][Full Text] [Related]
23. A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale. Khanna D; Denton CP; Assassi S; Kuwana M; Allanore Y; Domsic RT; Kleoudis C; Xu J; Csomor E; Seo C; Albulescu M; Tummala R; Al-Mossawi H; Kalyani RN; Del Galdo F Clin Exp Rheumatol; 2024 Aug; 42(8):1635-1644. PubMed ID: 39152751 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507 [TBL] [Abstract][Full Text] [Related]
25. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus. Chia YL; Tummala R; Mai TH; Rouse T; Streicher K; White WI; Morand EF; Furie RA J Clin Pharmacol; 2022 Sep; 62(9):1094-1105. PubMed ID: 35352835 [TBL] [Abstract][Full Text] [Related]
26. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Morand E; Pike M; Merrill JT; van Vollenhoven R; Werth VP; Hobar C; Delev N; Shah V; Sharkey B; Wegman T; Catlett I; Banerjee S; Singhal S Arthritis Rheumatol; 2023 Feb; 75(2):242-252. PubMed ID: 36369798 [TBL] [Abstract][Full Text] [Related]
27. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687 [TBL] [Abstract][Full Text] [Related]
28. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Kalunian KC; Furie R; Morand EF; Bruce IN; Manzi S; Tanaka Y; Winthrop K; Hupka I; Zhang LJ; Werther S; Abreu G; Hultquist M; Tummala R; Lindholm C; Al-Mossawi H Arthritis Rheumatol; 2023 Feb; 75(2):253-265. PubMed ID: 36369793 [TBL] [Abstract][Full Text] [Related]
29. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
30. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Furie RA; Bruce IN; Dörner T; Leon MG; Leszczyński P; Urowitz M; Haier B; Jimenez T; Brittain C; Liu J; Barbey C; Stach C Rheumatology (Oxford); 2021 Nov; 60(11):5397-5407. PubMed ID: 33956056 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Efficacy and Safety of Anifrolumab in Moderate-to-Severe Systemic Lupus Erythematosus. Cingireddy AR; Ramini N; Cingireddy AR Cureus; 2024 Jul; 16(7):e63966. PubMed ID: 39104974 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA; Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403 [TBL] [Abstract][Full Text] [Related]
33. Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial. Park JK; Kim M; Jung JI; Kim JY; Jeong H; Park JW; Winthrop KL; Lee EB Lancet Rheumatol; 2024 Jun; 6(6):e352-e360. PubMed ID: 38710192 [TBL] [Abstract][Full Text] [Related]
34. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Felten R; Scher F; Sagez F; Chasset F; Arnaud L Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735 [TBL] [Abstract][Full Text] [Related]
35. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Jayne D; Rovin B; Mysler EF; Furie RA; Houssiau FA; Trasieva T; Knagenhjelm J; Schwetje E; Chia YL; Tummala R; Lindholm C Ann Rheum Dis; 2022 Apr; 81(4):496-506. PubMed ID: 35144924 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Rovin BH; Teng YKO; Ginzler EM; Arriens C; Caster DJ; Romero-Diaz J; Gibson K; Kaplan J; Lisk L; Navarra S; Parikh SV; Randhawa S; Solomons N; Huizinga RB Lancet; 2021 May; 397(10289):2070-2080. PubMed ID: 33971155 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Merrill JT; van Vollenhoven RF; Buyon JP; Furie RA; Stohl W; Morgan-Cox M; Dickson C; Anderson PW; Lee C; Berclaz PY; Dörner T Ann Rheum Dis; 2016 Feb; 75(2):332-40. PubMed ID: 26293163 [TBL] [Abstract][Full Text] [Related]
38. Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials. Lee YH; Song GG Z Rheumatol; 2021 Dec; 80(10):988-994. PubMed ID: 33216191 [TBL] [Abstract][Full Text] [Related]
39. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Tummala R; Abreu G; Pineda L; Michaels MA; Kalyani RN; Furie RA; Morand EF Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33597205 [TBL] [Abstract][Full Text] [Related]
40. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S; Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]